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Axin is a negative regulator of the Wnt signalling pathway, and genetic alterations of AXIN1 have been suggested to be an important
factor of carcinogenesis in some tumours. The objective of this study was to clarify the clinicopathologic and prognostic significance of
Axin in oesophageal squamous cell carcinoma (SCC). Immunohistochemical staining for Axin was performed on surgical specimens
obtained from 81 patients with oesophageal SCC. Western and Northern blottings were performed on proteins and RNA from
oesophageal SCC cell lines. Then polymerase chain reaction–single-strand conformational analysis (PCR–SSCP) was performed on
DNA from oesophageal SCC patients and cell lines. Axin expression was found to be correlated inversely with depth of invasion,
lymph node metastasis, and lymphatic invasion. Although univariate analysis showed Axin to be a negative predictor, multivariate
analysis showed that it was not an independent prognostic marker. In all but one of the seven cell lines examined, the levels of protein
expression were equivalent to RNA expression. PCR–SSCP showed that five patients and three cell lines had polymorphisms in
exon 4 or 5 of the AXIN1 gene, but none of the 81 patients with oesophageal SCC had mutations. Our findings suggest that reduced
expression of Axin is correlated with tumour progression of oesophageal SCC. However, additional studies will be necessary to
elucidate the mechanism responsible for loss of Axin expression in tumour cells.
British Journal of Cancer (2003) 88, 1734–1739. doi:10.1038/sj.bjc.6600941 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: Axin; oesophageal squamous cell carcinoma; carcinogenesis; immunohistochemistry; single nucleotide polymorphism
                                           
The Wnt signalling pathway regulates cellular proliferation,
differentiation, morphology, and motility in vertebrates and
invertebrates (Zeng, 1997; Akiyama, 2000; Bienz and Clevers,
2000). Axin, a negative regulator of this pathway, promotes
phosphorylation of serine/threonine in exon 3 of b-catenin by
forming a complex with adenomatous polyposis coli (APC) and
glycogen synthase kinase-3b (GSK-3b) (Ikeda et al, 1998, 2000;
Kishida et al, 1998). Phosphorylated b-catenin is quickly degraded
via a ubiquitin–proteasome pathway in the cytoplasm (Nakamura,
1997). Upon Wnt signalling, because the activity of Axin complex
is blocked through Dishevelled, phosphorylation of b-catenin is
suppressed and b-catenin accumulates in the cytoplasm. Accumu-
lated b-catenin protein is translocated to the nucleus as a
coactivator for the T-cell factor (TCF)/lymphocyte enhancer-
binding factor (LEF) family (Morin et al, 1997; He et al, 1998)
and activates the transcription of Wnt target genes such as c-myc
(He et al, 1998) or cyclin D1 (Tetsu and McCormick, 1999).
The wild-type Axin gene (AXIN1) is regarded as a tumour
suppressor in some kinds of tumours. AXIN1 mutations have been
reported in a colon carcinoma cell line (Webster et al, 2000),
hepatocellular carcinoma (HCC) (Satoh et al, 2000; Laurent-Puig
et al, 2001), ovarian endometrioid adenocarcinoma (Wu et al,
2001), and sporadic medulloblastoma (Dahmen et al, 2001). In
HCC cell lines with AXIN1 mutations, accumulation of b-catenin in
the cytoplasm or nucleus has been observed, and the transcription
activity of TCF4 is regulated positively (Satoh et al, 2000).
Oesophageal carcinoma is one of the most lethal gastrointestinal
malignancies. Despite recent advances in therapy and manage-
ment, the overall 5-year survival rate remains at less than 50%
(Ando et al, 1997; Collard et al, 2001). In future, it will be possible
to identify prognostic markers and thus select the most suitable
therapy for each tumour.
Although several studies have been performed to elucidate the
relation between Axin expression and tumours in several organs,
to our knowledge, there have been no reports related to
immunohistochemical expression of Axin in oesophageal carcino-
ma, or the association between Axin expression and prognosis.
To clarify whether Axin expression is a significant prognostic
factor, we examined immunohistochemically the relation between
Axin expression, pathologic tumour variables, and prognosis in
patients with oesophageal squamous cell carcinoma (SCC). Next,
to clarify the mechanism of regulation of Axin expression, we
performed Western and Northern blot analyses of oesophageal
SCC cell lines. We also searched for mutations of AXIN1 that were
considered to activate the Wnt signalling pathway.
MATERIALS AND METHODS
Patients
Surgical specimens were obtained from 81 patients (70 males and
11 females) with oesophageal SCC, who underwent potentially
curative surgery at the Department of Surgery I, Gunma University
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yFaculty of Medicine, between 1983 and 2000. The age range of the
patients was 40–78 years, and the mean age 61.3 years. Tumour
stage and disease grade were classified according to the fifth
edition of the TNM Classification of the International Union
Against Cancer (UICC). None of the patients had received
irradiation or chemotherapy before surgery, nor did any of them
have haematogenic metastases at the time of surgery. Patients who
underwent noncurative surgery and/or had inadequate follow-up
were not included in the study. Postoperative chemotherapy
and/or radiation therapy were not performed until recurrence of
the tumour was confirmed by radiologic or endoscopic examina-
tion. All patients signed informed consent forms according to our
institutional guidelines.
Cell culture
Seven human oesophageal SCC cell lines were grown on plastic
tissue culture dishes: TE-series 1, 2, 8, 13, and 15 (gift from Dr T
Nishihira, Tohoku University, Sendai, Japan) (Nishihira et al,
1993), and TT and TTn (JCRB0262 and 0261, gift from Dr K
Takahashi, Tohoku University, Miyagi, Japan). The TE-series were
cultured in RPMI 1640 medium (Sigma, St Louis, MO, USA)
containing 10% foetal bovine serum and antibiotics (100Uml
 1
penicillin and 100mgml
 1 streptomycin); TT and TTn were
cultured in a 1:1 mixture of Dulbecco’s modified Eagle medium
and Ham’s F-12 medium (Sigma) containing 10% foetal bovine
serum and antibiotics, as described above.
Immunohistochemistry for Axin
Resected specimens were fixed with 10% neutral-buffered formalin
and embedded in paraffin blocks. Sections, 4mm thick, were
deparaffinised with xylene, rehydrated, and incubated with fresh
0.3% H2O2 in methanol for 30min at room temperature. After
rehydration through a graded ethanol series, tissue sections for the
Axin study were autoclaved in 20mM citric acid buffer at 1201C for
2min and then cooled to 301C. After incubation with normal goat
serum (Histofine SAB-PO (R) kit; Nichirei, Tokyo, Japan), the
tissue sections were applied for 30min and removed by blotting.
The sections were then incubated overnight with primary rabbit
anti-Axin polyclonal antibody (Zymed Laboratories Inc., San
Francisco, USA) at a dilution of 1:100 in PBS containing 1%
bovine serum albumin at 41C, washed in PBS, and incubated with
secondary antibody for 30min at room temperature. Immuno-
histochemistry was performed with the SAB-PO (R) kit. The
chromogen was 3,30-diaminobenzidine tetrahydrochloride, applied
as a 0.02% solution containing 0.0055% H2O2 in 50mM Tris-HCl
buffer, pH 6.0. The sections were lightly counterstained with
haematoxylin. Negative controls were prepared by substituting
normal rabbit serum for each primary antibody, and no detectable
staining was evident.
Evaluation of Axin expression
The mean Axin expression rate in the 81 primary tumours was
almost 50%. Therefore, when 50% or more of the tumour cells in a
given specimen were positively stained to the same degree as
normal epithelium, the sample was graded as Axin preserved.
When fewer than 50% of the tumour cells were stained to the same
degree as normal epithelium, the sample was graded as having
reduced expression.
Western blot analysis
Protein extraction and immunoblotting were performed as
described previously (Kain et al, 1994). Lysates from exponentially
growing cell lines were prepared in a buffer containing 20mM Tris-
HCl, pH 7.5, 150mM NaCl, 1% Nonidet P-40, 1% aprotinin and
1m M phenylmethylsulphonyl fluoride. The protein concentration
was determined with a BCA Protein Assay Kit (Pierce, Rockford,
IL, USA). In all, 30mg of protein from each cell line was
resuspended in sodium dodecyl sulphate (SDS) sample buffer
(100mM Tris-HCl, pH 8.8; 0.01% bromophenol blue; 36% glycerol;
4% SDS) containing 1mM dithiothreitol, boiled for 5min, and
subjected to 5–20% Ready Gels J (Bio-Rad, Tokyo, Japan).
Proteins were electrotransferred to a Hybond enhanced chemi-
luminescence nitrocellulose membrane (Amersham Pharmacia
Biotech, Buckinghamshire, UK). Proteins were immunoblotted
with anti-rabbit Axin antibody (Zymed Laboratories Inc.), and
bands were detected using an enhanced chemiluminescence
detection system (Amersham Pharmacia Biotech). For reblotting,
membranes were stripped according to the manufacturer’s
protocol. Anti-b-actin (Sigma) antibody served as the control.
Northern blot analysis
Total RNA was extracted from the cells with Trizol Reagent (Gibco
BRL, Rockville, MD, USA). In all, 20mg of RNA per lane was
electrophoresed in 1.2% agarose gels containing 2.2moll
 1
formaldehyde, and blotted onto a Biodyne B membrane (Pall,
Tokyo, Japan). The cDNA probe was labelled using a Random
Primer DNA Labelling Kit (Roche Molecular Biochemicals,
Mannheim, Germany) and [a-
32P]dCTP (Amersham Pharmacia
Biotech). The rabbit Axin probe was digested from pcDNA3-FLAG/
rAxin (full-length) (gift from Dr A Kikuchi, Hiroshima University,
Hiroshima, Japan). Membranes were prehybridised at 421C for
more than 2h and hybridised overnight at 421C after staining with
methylene blue to verify the quality and quantity of the RNA. The
membranes were washed in 2 SSC, 0.1% SDS for 15min and
0.2 SSC, 0.1% SDS for 15min at 421C. The washed membrane
was exposed to X-ray film under an intensifying screen. A human
18S probe served as the control.
DNA extraction and polymerase chain reaction–
single-strand conformational polymorphism
(PCR–SSCP) analysis
Small pieces of normal tissue and tumour tissue were frozen in
liquid nitrogen and stored at  801C until DNA extraction. High-
molecular-weight DNA samples from seven oesophageal SCC cell
lines, as well as fresh-frozen tumour and normal tissues from the
81 patients, were prepared by the phenol–chloroform method
after treatment with SDS and proteinase K.
All samples were examined by PCR–SSCP analysis for muta-
tions in exons 2–5 of AXIN1, which correspond to the binding
sites of b-catenin and GSK-3b. Each exon was amplified using the
nine sets of PCR primers published previously (Satoh et al, 2000).
Each target sequence was amplified in a 20-ml reaction volume
containing 10–20ng of genomic DNA, 2mM dNTPs, 10mM Tris-
HCl, pH 8.3, 50mM KCl, 2mM MgCl2, 0.2mM each primer, 1.5mCi of
[a-32P]dCTP (Amersham Japan, Tokyo, Japan), and 1U of Taq
DNA polymerase (Applied Biosystems, Foster City, CA, USA).
These samples were amplified for 35 cycles of denaturation at 951C
for 30s, annealing at 60 or 611C for 30s, and extension at 721C for
1min. The PCR products were electrophoresed in 5% polyacry-
lamide with 5% glycerol gels and autoradiographed for 24h on
Kodak XAR film (Eastman Kodak, Rochester, NY, USA).
DNA sequencing
DNA fragments were cut out of the dried gels and reamplified by
PCR with the corresponding sets of primers for 40 cycles.
Amplified DNA fragments were purified with a QIA quick PCR
Purification Kit (QIAGEN, Hilden, Germany) and sequenced with
an ABI PRISM 3100 (Applied Biosystems, Foster City, CA, USA).
Axin expression in oesophageal squamous cell carcinoma
M Nakajima et al
1735






























Statistical analysis was performed by the w
2 test, the Fisher exact
test, and the Mann–Whitney U-test to assess the correlation
between Axin immunohistochemical positivity and parameters. A
Cox proportional hazards model for risk ratio was used to assess
the simultaneous contribution of Axin expression to survival.
RESULTS
Immunohistochemistry of Axin
Immunoreactivity for Axin was strongly positive in normal
stratified squamous epithelium of the oesophagus, and was
localised in the cytoplasm (Figure 1A). Several staining patterns
were observed for the expression of Axin in tumour tissues. Some
tumours showed a diffuse decrease in Axin expression, others had
both preserved and reduced expression in cell colonies, and others
showed highly preserved expression (Figure 1B, C).
Relation between Axin expression and clinicopathologic
features
The correlation between the clinicopathologic characteristics of
patients with oesophageal SCC and the expression of Axin in their
tumours is summarised in Table 1. There were significant inverse
correlations between Axin expression and depth of invasion
(P¼0.0235), lymph node metastasis (P¼0.0255), and lymphatic
invasion (P¼0.0058). However, there was no significant associa-
tion with patient age, gender, tumour location, grade, pathologic
stage, intraepithelial spread, or blood vessel invasion.
As a strong inverse correlation between Axin expression and
lymphatic invasion was recognised, we examined the Axin status of
tumour cells that had infiltrated lymph vessels. The result revealed
that most of the cases positive for lymphatic invasion had reduced
or no Axin expression (50 out of 56 cases).
Prognostic significance of Axin expression
To clarify whether Axin expression is a significant prognostic
marker of patients with oesophageal SCC, univariate and multi-
variate survival analyses were performed. In univariate analyses by
the Cox model, Axin negativity, pT classification, pN classification,
pM classification, pStage, and lymphatic invasion were identified
as negative predictors. In multivariate analyses, pT classification,
but not Axin, was recognised as an independent prognostic factor
(Table 2).
Expression of Axin at the protein level in cultured cells
Expression of Axin was characterised at the protein level in seven
oesophageal SCC cell lines. Although all of these seven cell lines
were originally derived from oesophageal SCC, Western blotting
revealed different levels of Axin expression (Figure 2A). Axin was
expressed at high levels in TE1, TE15, TT, and TTn, and there was
very weak expression in TE2, TE8, and TE13.
Expression of Axin at the mRNA level in cultured cells
As there were marked variations in the level of expression of Axin
protein in the cultured cell lines, Northern blotting was performed
to examine the underlying mechanisms of the effects of Axin on
tumour cell regulation. This analysis indicated that levels of mRNA
expression were equivalent to levels of Axin protein expression,
with the exception of the TE8 line, in which Axin expression was
reduced in comparison with protein expression (Figure 2B).
Figure 1 Photographs of tissue sections immunostained for Axin. (A)
Axin was detected in the cytoplasm in normal oesophageal squamous
epithelia. (B) Axin expression was highly preserved (Axin-preserved type).
(C) Axin was partly detected in the cytoplasm in tumour cells, but
expression partly disappeared in the peripheral cells of tumour nests (Axin-
reduced type). Black bar¼100mm.
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yMutation of the AXIN1 gene in oesophageal SCC
None of the 81 patients with oesophageal SCC had mutations, but
five patients and three cell lines showed polymorphisms in the
AXIN1 gene (Figure 3, Table 3).
We confirmed three previously published single-nucleotide
polymorphisms (SNPs) (Lin et al, 2000; Dahmen et al, 2001).
One polymorphism resulted in an amino-acid substitution, and the
others were silent SNPs. However, there was no novel polymorph-
ism or silent mutation.
DISCUSSION
Axin is a negative regulator of the Wnt signalling pathway. It
accelerates phosphorylation and ubiquitination of b-catenin, thus
inhibiting importation of b-catenin to the nucleus and controlling
cell proliferation. Although an association of Axin with carcino-
genesis has been reported in colon cancer cell lines (Webster et al,
2000), HCC (Satoh et al, 2000; Laurent-Puig et al, 2001) and
medulloblastoma (Dahmen et al, 2001), to our knowledge there has
been no report concerning oesophageal SCC. Therefore, we
investigated the association between Axin expression and oeso-
phageal SCC.
First, we performed an immunohistochemical study of the
correlation between Axin expression and clinicopathologic factors
in patients with oesophageal SCC. Axin expression was seen in the
cytoplasm in normal oesophageal stratified squamous cells and
Table 1 Correlation between clinicopathologic characteristics and Axin
expression
Axin expression
Parameters n Reduced Preserved P-value
Age (mean7s.d., years) 61.378.5 61.978.6 0.7676
Gender
Male 70 32 38
Female 11 6 5 0.5853
Location
Cervical 1 1 0
Upper thoracic 10 6 4
Mid-thoracic 50 23 27
Lower thoracic 20 8 12 0.3218
Grade
Well 21 9 12
Moderate 39 15 24
Poor 21 14 7 0.1497
TNM classification
T
T1 31 8 23
T2 12 8 4
T3 32 18 14
T4 6 4 2 0.0235
a
N
N0 34 11 23
N1 47 27 20 0.0255
a
M
M0 66 29 37
M1 15 9 6 0.5136
Stage
I2 1 4 1 7
IIA 12 6 6
IIB 14 6 8
III 19 13 6
IVA 3 2 1
IVB 12 7 5 0.0750
Infiltrative growth pattern
a 20 6 14
b 56 29 27
g 5 3 2 0.2044
Intraepitherial spread
( )4 1 1 8 2 3
(+) 40 20 20 0.5825
Lymphatic invasion
( )2 5 6 1 9
(+) 56 32 24 0.0058
a
Blood vessel invasion
( )4 6 2 0 2 6
(+) 35 18 17 0.4775
s.d.¼standard deviation;
aSignificant.
Table 2 Univariate and multivariate analysis of Axin expression and
pathologic factors








pT classification 8.245(2.889–23.527) o0.0001
b
pN classification 3.204(1.447–7.094) 0.0041
b
pM classification 3.336(1.510–7.371) 0.0029
b
pStage classification 8.338(1.996–34.842) 0.0036
b
Lymphatic invasion 2.591(1.127–5.956) 0.0250
b
Blood vessel invasion 1.579(0.807–3.093) 0.1824
Multivariate
Axin 1.352(0.656–2.784) 0.4137
pT classification 5.930(1.361–25.848) 0.0178
b
pN classification 1.503(0.488–4.628) 0.4778
pM classification 1.510(0.621–3.671) 0.3636
pStage classification 1.031(0.117–9.062) 0.9783
Lymphatic invasion 1.374(0.479–3.940) 0.5549
aCI¼confidence interval.
bSignificant.
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Figure 2 Western and Northern blotting of Axin in human oesophageal
SCC cell lines. (A) Expression of Axin protein (top) and b-actin (bottom),
as determined by Western blotting in various carcinoma cell lines. b-actin
protein levels were used as controls for sample loading. (B) Expression of
Axin mRNA as determined by Northern blotting. Top is Axin and bottom
is 18S. mRNA expression is equivalent to protein expression except in the
TE8 line. 18S was used as a control.
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ytumour cells. In tumour tissues, Axin expression was inversely
correlated with depth of invasion, lymph node metastasis, and
lymphatic invasion. When we examined the Axin status of tumour
cells that had invaded lymph vessels, their Axin expression was
reduced or lost in most cases, suggesting that reduced expression
of Axin initiates or promotes tumour progression. As Axin is a
negative regulator of b-catenin/TCF-dependent cell proliferation
(Kikuchi, 1999) and carcinogenesis (Barker et al, 2000), loss of
Axin expression in oesophageal SCC may lead to tumour
progression.
Western blotting revealed marked variation in the intensity of
Axin expression, corresponding to the results of immunohisto-
chemistry of the tumour tissues. During oesophageal carcinogen-
esis, some error may occur in the process of Axin protein
production. Therefore, Northern blotting was performed to
investigate the translation status of each tumour cell line. The
status of RNA expression was variable, but the levels of Axin
expression were equivalent to those of Axin protein with the
exception of the TE8 cell line. That is, six of the cell lines – apart
from the TE8 line – had no errors of translation. In these six lines,
transcription errors might have occurred, because their intensity
of Axin expression was weak compared with that in TE8. Thus, in
the TE8 line, some errors might have occurred at the level of
translation, or after. Further examination of this possibility will be
needed.
Next, PCR–SSCP was performed to examine whether the
variation of mRNA expression was derived from any genetic
alterations of the GSK-3b or b-catenin binding site of Axin DNA.
Five patients showed polymorphisms and three cell lines showed
silent mutations in the AXIN1 gene, but no pathogenetic gene
mutation was detected. Although the frequency of AXIN1 deletions
in medulloblastoma is 12% (Dahmen et al, 2001) and a similar
figure for genetic alterations has been demonstrated in HCC (Satoh
et al, 2000), the results of our mutational analysis of oesophageal
SCC were different, suggesting that association of AXIN1 muta-
tions with carcinogenesis is rare in oesophageal SCC. Similarly,
one previous study detected no mutations in paediatric renal
tumours (Miao et al, 2002). However, in addition to allelic losses,
inactivation of transcription because of methylation in the
promoter region could be responsible for downregulation of Axin.
This possibility remains to be examined.
To examine whether Axin regulates only the Wnt-b-catenin-
TCF/LEF pathway and determine which factors in this pathway
would be good predictors of prognosis, we also analysed relations
among Axin, b-catenin, and GSK-3b using immunohistochemistry
and Western blotting. There was no significant association
between either Axin and b-catenin, or between b-catenin and
clinicopathologic factors (data not shown). Furuhashi et al (2001)
have reported that Axin facilitates Smad3 activation in the TGFb
signalling pathway. Ishiguro et al (2001) have reported that
transcription of AXIN1 upregulated (AXUD1), a gene induced by
AXIN1, is independent of the TCF/LEF complex and that AXUD1 is
frequently downregulated in some tumours. Oesophageal SCC may
be regulated in a similar manner by an unknown pathway. GSK-3b
expression was found to have no association with Axin expression
or clinicopathologic factors (data not shown). Thus, there may be
other pathways besides the Wnt signalling pathway that participate
in carcinogenesis.
In HCC cells, adenovirus-mediated gene transfer of wild-type
AXIN1 induces apoptosis, regardless of the existence of AXIN1
mutations (Satoh et al, 2000). Thus, transfer of wild-type Axin
might offer a possible approach for gene therapy of oesophageal
SCC.
In conclusion, Axin expression appears to be useful for
predicting the prognosis of patients with oesophageal SCC,
because Axin expression declines with tumour progression.
Additional studies will no doubt elucidate the mechanism
responsible for loss of Axin expression in tumour cells.
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Figure 3 Mutation analysis of Axin. (A) Two aberrant bands of tumour
DNA were detected in SSCP (arrow). (B) DNA sequencing of excised and
reamplified DNA products of TE2 revealed C-T transition in codon 563
without amino-acid substitution. It was judged to be a silent SNP.
Table 3 Mutational analysis of Axin gene in oesophageal SCC
Case Age (year)/gender Exon Base change
a aa change Codon
30 66/male 4 G1256A Yes (Arg-Cys) 419
40 54/male 4 G1256A Yes (Arg-Cys) 419
13 64/female 5 G1396A No (Ser-Ser) 485
15 62/male 5 G1396A No (Ser-Ser) 485
17 59/male 5 G1396A No (Ser-Ser) 485
TE1 5 G1396A No (Ser-Ser) 485
TE2 5 C1690T No (Asp-Asp) 563
TE13 5 C1690T No (Asp-Asp) 563
aAmino-acid (aa) positions according to GenBank accession no. AF009674.
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